Ohlstein E[au] - Search Results

Year	Number of Results
1979	1
1980	1
1981	3
1982	1
1983	1
1984	2
1985	3
1986	2
1987	6
1988	8
1989	5
1990	8
1991	5
1992	9
1993	8
1994	17
1995	15
1996	12
1997	5
1998	20
1999	6
2000	19
2001	13
2002	10
2003	3
2004	5
2005	4
2006	3
2007	2
2008	4
2009	3
2010	1
2012	1
2013	1
2015	1
2022	0

1

Endothelin receptor antagonists.

Elliott JD, Ohlstein EH, Peishoff CE, Ellens HM, Lago MA. Elliott JD, et al. Among authors: ohlstein eh. Pharm Biotechnol. 1998;11:113-29. doi: 10.1007/0-306-47384-4_6. Pharm Biotechnol. 1998. PMID: 9760678 Review. No abstract available.

2

New strategies in drug discovery.

Ohlstein EH, Johnson AG, Elliott JD, Romanic AM. Ohlstein EH, et al. Methods Mol Biol. 2006;316:1-11. doi: 10.1385/1-59259-964-8:1. Methods Mol Biol. 2006. PMID: 16671397 Free PMC article. Review.

3

Drug discovery in the next millennium.

Ohlstein EH, Ruffolo RR Jr, Elliott JD. Ohlstein EH, et al. Annu Rev Pharmacol Toxicol. 2000;40:177-91. doi: 10.1146/annurev.pharmtox.40.1.177. Annu Rev Pharmacol Toxicol. 2000. PMID: 10836132 Review.

4

Therapeutic modulation of transcription factor activity.

Emery JG, Ohlstein EH, Jaye M. Emery JG, et al. Among authors: ohlstein eh. Trends Pharmacol Sci. 2001 May;22(5):233-40. doi: 10.1016/s0165-6147(00)01661-8. Trends Pharmacol Sci. 2001. PMID: 11339974 Review.

5

Techniques: Cardiovascular pharmacology and drug discovery in the 21st century.

Douglas SA, Ohlstein EH, Johns DG. Douglas SA, et al. Among authors: ohlstein eh. Trends Pharmacol Sci. 2004 Apr;25(4):225-33. doi: 10.1016/j.tips.2004.02.013. Trends Pharmacol Sci. 2004. PMID: 15063087 Review.

6

International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function.

Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H, Vaudry D. Vaudry H, et al. Among authors: ohlstein eh. Pharmacol Rev. 2015;67(1):214-58. doi: 10.1124/pr.114.009480. Pharmacol Rev. 2015. PMID: 25535277 Review.

7

Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets.

Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR Jr. Ohlstein EH, et al. Med Res Rev. 1996 Jul;16(4):365-90. doi: 10.1002/(SICI)1098-1128(199607)16:4<365::AID-MED4>3.0.CO;2-V. Med Res Rev. 1996. PMID: 8798180 Review.

8

Signal transduction mechanisms mediating the vascular actions of endothelin.

Douglas SA, Ohlstein EH. Douglas SA, et al. Among authors: ohlstein eh. J Vasc Res. 1997 May-Jun;34(3):152-64. doi: 10.1159/000159219. J Vasc Res. 1997. PMID: 9226297 Review.

9

Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.

Ruffolo RR Jr, Feuerstein GZ, Ohlstein EH. Ruffolo RR Jr, et al. Among authors: ohlstein eh. Am J Hypertens. 1998 Jan;11(1 Pt 2):9S-14S. doi: 10.1016/s0895-7061(97)00423-8. Am J Hypertens. 1998. PMID: 9503101 Review.

10

Endothelin and platelet function.

Ohlstein EH, Storer B, Nambi P, Given M, Lippton H. Ohlstein EH, et al. Thromb Res. 1990 Mar 15;57(6):967-74. doi: 10.1016/0049-3848(90)90163-7. Thromb Res. 1990. PMID: 2116686

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results